Key figures
- Revenue: $2.9 million (prior period: $1.9 million; up 53.9%)
- Result: net loss after tax of $3.4 million (prior period: net loss after tax of $3.5 million; 2.8% smaller)
- Operating profit: $3.0 million (a loss) (prior period: $3.3 million (a loss))
- Dividend: none declared for the period
FY2026 results
Total revenue for the period was $2.9 million. Operating profit was $3.0 million (a loss). The company declared no dividend was declared for the period for the period.
Compared with the prior period
Revenue was up 53.9% on $1.9 million in the prior period. Operating profit was $3.3 million (a loss) in the prior period, and the statutory result was 2.8% smaller than the a net loss after tax of $3.5 million recorded in the prior period.
In the company's words
Sales are anticipated to maintain an upward trajectory through FY27 as Rua continues to seek new opportunities to grow revenue and margin, with ongoing investment in new product development across our key markets.
---
Source: Rua Bioscience Limited, "Preliminary Unaudited Annual Results" (27 August 2026), https://www.nzx.com/announcements/478751.
Updated 24 October 2026: rewritten so that every figure is taken directly from the company's announcement. Earlier versions of these automated articles contained errors. This article was generated from the company's NZX results announcement by NZXplorer's automated reporting system. Every figure is taken from that announcement. It is provided for information only and is not financial advice.